Raising Capital in 2023: A Focus on Therapeutics. An interactive panel discussion with Silicon Valley Bank and Early Stage Investors.
Join Silicon Valley Bank, 5am Ventures, Pivotal Ventures, MBC Biolabs, VenBio, and JLABS as we host an interactive discussion on:
Raising Capital in 2023: A Focus on Therapeutics: Nov 2nd 3pm-5.30pm (including a happy hour with refreshments)
Raising capital as a biotech founder is always hard, but particularly so these days.
SVB and MBC BioLabs are hosting a panel of corporate and institutional VC’s to better understand the landscape and to peer into the crystal ball to see what the future may hold for us all.
We will begin with a look at the macroeconomic drivers of biotech investment capital: i.e. How well have VC’s done at raising capital for their funds this year?
Additionally, how have recent trends affected where VCs want to invest?, are VC’s actively investing in newco’s or are they moving toward company creation models?, how does the IRA affect early stage investments in small large molecules in various therapeutic areas? And, what does a founder need to do in 2023 to get the attention of VCs?
These (and many more) will be the questions posed to the panelists to shed light on what’s in store for founders aiming to raise in 20232024.
We look forward to connecting with all entrepreneurs on site, and, please stay for our happy hour post panel discussion for extra networking opportunities refreshments will be served!
Moderator: Anton Xavier, Director SVB Life Sciences, A Division of First Citizen’s Bank
Co Host: Carlo Casuga, Vice President SVB Life Sciences, A Division of First Citizen’s Bank
Panelists:
Max Farina MD, MBA (Senior Associate: 5am Ventures)
Brian Mills PhD (Senior Associate: Pivotal Life Sciences)
Zach Collins PhD (Principal: Mission Biocapital)
Yvonne Yamanaka PhD (Principal: venBio Partners)
Christopher Haskell PhD (Head: JLABS San Francisco Bay Area)